Cholangiography Using 64-Multi-Detector Row Computed Tomography in the Normal Dog by Miller, Jennifer Wooley
Mississippi State University 
Scholars Junction 
Theses and Dissertations Theses and Dissertations 
1-1-2014 
Cholangiography Using 64-Multi-Detector Row Computed 
Tomography in the Normal Dog 
Jennifer Wooley Miller 
Follow this and additional works at: https://scholarsjunction.msstate.edu/td 
Recommended Citation 
Miller, Jennifer Wooley, "Cholangiography Using 64-Multi-Detector Row Computed Tomography in the 
Normal Dog" (2014). Theses and Dissertations. 1057. 
https://scholarsjunction.msstate.edu/td/1057 
This Graduate Thesis - Open Access is brought to you for free and open access by the Theses and Dissertations at 
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of 
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com. 
 













Automated Template B: Created by James Nail 2011V2.1




Submitted to the Faculty of
Mississippi State University
in Partial Fulfillment of the Requirements
for the Degree of Master of Science
in Veterinary Medical Science


















































































      
    
 
   
 
 
Name: Jennifer Wooley Miller
Date of Degree: May 16, 2014
Institution: Mississippi State University
Major Field: Veterinary Medical Science
Major Professor: Erin Brinkman-Ferguson
Title of Study: Cholangiography using 64-multi-detector row computed tomography in 
the normal dog
Pages in Study: 85
Candidate for Degree of Master of Science
Hepatobiliary disease can sometimes be difficult to diagnosis due to non-specific
clinical signs, and diagnostic imaging is a vital tool in diagnosing these diseases.  Multi-
slice computed tomographic cholangiography (MSCTC) is a non-invasive way to obtain 
high quality images of the hepatobiliary system. Our objectives were to determine the 
best technique for performing MSCTC in normal dogs with regards to contrast agent, 
dose, and optimal time to imaging.  Our test subjects included eight normal adult hounds.  
Four dogs were administered Cholografin and the other four Biliscopin. Two dose
groups were established with four dogs receiving 0.5mL/kg and four receiving 1 mL/kg. 
Our results demonstrated that MSCTC is feasible in normal dogs and produces high 
quality images of the hepatobiliary system.  The contrast agent Biliscopin at the higher
dose subjectively produced the best quality images. The optimal time to image patients 
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INTRODUCTION
Background Information and Project Significance 
Hepatobiliary diseases are being diagnosed more commonly in small animals due 
to newer imaging modalities and techniques becoming more widely available. Imaging is 
a critical tool in the diagnosis of these diseases.  Many animals with hepatobiliary disease
go undiagnosed until their disease has progressed to the late stages due to the non-
specific clinical signs associated with hepatobiliary disease.  Hepatobiliary disease can
also sometimes be mistaken for other intra-abdominal diseases due to similar clinical 
signs.  There is a need for a better way to obtain high quality cross-sectional and three-
dimensional images of the hepatobiliary system non-invasively in small animals. 
Current modalities available for hepatobiliary imaging in small animals include 
radiography, ultrasound, computed tomography, nuclear scintigraphy, intravenous 
cholangiography combined with radiography, magnetic resonance
cholangiopancreatography, endoscopic retrograde cholangiography, and percutaneous 
transhepatic cholangiography.1-4 Abdominal radiography is widely available and is 
recommended as an initial diagnostic step in dogs suspected of having hepatobiliary
disease.  Unfortunately, it is often an insensitive method for diagnosing hepatobiliary
disease. Ultrasonography is a non-invasive technique that is readily available, but it is 









   
  
   
 
   
   
   
    
  
    




   
radiography, it provides inferior images of peripheral intrahepatic bile ducts when 
compared with other modalities.1, 2, 4, 5 Gas in the gastrointestinal tract can also limit 
ultrasonographic evaluation of biliary structures in some dogs.  Nuclear scintigraphy is 
used in dogs to diagnose biliary obstructions.  It is non-invasive, but requires the use of 
radioisotopes and has limited availability.  Percutaneous transhepatic cholangiography
and endoscopic retrograde cholangiography, which are considered the gold standard in 
hepatobiliary imaging in humans, are techniques that provide excellent visualization of
the bile ducts.4-6 These techniques have also been shown to produce high quality images 
of the hepatobiliary tract in small animals.1-3, 5, 7 However, they are invasive, costly, can 
be technically demanding, and carry significant risk to the patient.1-3 Magnetic resonance
cholangiopancreatography is non-invasive but can be prone to artifact, provides little 
functional information, has limited availability, and is costly.5, 6, 8 
Multi-slice computed tomography (MSCT) has been shown in humans to have a
high diagnostic accuracy in the fields of abdominal, thoracic, and cardiovascular
imaging.9 In veterinary medicine, MSCT has also been shown to be valuable in imaging
multiple body systems, including the adrenal glands, the hepatic portal vasculature, and 
the intestines.10 MSCT allows for large volumes of data to be acquired rapidly and be
reconstructed into detailed two-dimensional and three-dimensional images.5, 9 Multi-slice
computed tomographic cholangiography (MSCTC) combines the use of MSCT with an 
intravenous iodinated contrast agent that is excreted specifically through the biliary
system.  It has been shown in multiple studies performed in humans to be non-invasive
and produce diagnostic quality studies of the biliary tract beyond just that obtained with 













   
  







MSCTC has been performed successfully for the description of normal biliary anatomy in 
porcine subjects.6 MSCTC using a 64-slice multi-detector row scanner has not yet been 
described in dogs.
Indications for performing MSCTC in humans include but are not limited to
cholelithiasis/choledocholithiasis, anomalous conditions of the bile ducts, unexplained
upper abdominal pain, dilation of biliary ducts noted on ultrasound, neoplasia of the liver, 
biliary tract, and associated structures, biliary tract rupture and stricture, and pre-and 
post-surgical planning .5, 6, 8, 11, 13 Indications for imaging the canine biliary tract are
similar and include but are not limited to cholelithiasis/choledocholithiasis, cholecystitis, 
gallbladder mucoceles, neoplasia of the liver and biliary tract, or extra-hepatic biliary
tract rupture or obstruction.1-4 
Research Objectives
The purpose of our study was to describe the normal cross-sectional and three-
dimensional biliary anatomy of the normal dog by developing a technique for performing
MSCTC.  With regards to technique, we also wanted to determine the optimal time for
imaging following contrast injection, the optimal contrast media, and contrast dose.
We hypothesized that cholangiography using multi-slice computed tomography
would be feasible in the normal dog and would produce high quality images of the biliary
system.  We also hypothesized that we would be able to reconstruct our raw data using
multiple reconstruction formats to generate detailed two and three-dimensional images.  
With regards to contrast dose, we hypothesized that the higher dose of contrast would 
produce better quality images. We also hypothesized there would not be a difference in 









   
  
   
  
  
   
 
   
    
   





Normal Biliary Anatomy and Physiology
Bile is produced by the hepatocytes and excreted into the bile canaliculi, which lie 
in between the cells.1, 14 The canaliculi all unite and form biliary ductules which then 
turn into interlobular ductules.14 Larger interlobular ducts form from the anastomosis of 
small interlobular ductules.14 Lobar intrahepatic ducts are then formed from interlobular 
ducts uniting.14 The extrahepatic ducts arise from the intrahepatic ducts and consist of 
the hepatic ducts.14 Variations in the number of hepatic ducts and their terminal location
are commonly seen.14, 15 
The cystic duct, which drains the neck of the gallbladder, merges with the
gallbladder and two or more hepatic ducts to form the bile duct.1, 14 (Figure 2.1)  The bile
duct exits the porta hepatis ventral to the portal vein and terminates in the lumen of the
duodenum at the major duodenal papilla near the pancreatic duct.1 (Figure 2.2)  The distal 
portion of the bile duct that travels through the lesser omentum along the hepatoduodenal 
ligament is typically 5cm in length and 2.5mm in diameter.14, 16 The intramural portion 
of the bile duct is approximately 1.5 to 2 cm in length.14, 16 (Figure 2.3 A) The intramural 
portion of the bile duct is surrounded by a double layer of smooth muscle.14 The outer
layer consists of the tunica muscularis portion of the duodenum and the inner layer is 




   
  






the musculus sphincter ampullae hepatopancreaticae and the musculus sphincter ductus 
choledochi which cause the excretion of bile to be largely dependent upon duodenal 
activity.14 Bile flows from the bile canaliculi into the interlobular ducts and then into the
lobar ducts before exiting the liver.14, 16 The lobar ducts then drain into the hepatic ducts 
and pass bile into the bile duct.14, 16 
Figure 2.1 Schematic of gallbladder and hepatic ducts, visceral aspect








Figure 2.2 Bile, hepatic, and pancreatic ducts





   
  
  
   
    
    
  
 
   
 
    
Figure 2.3 Intramural course of the bile duct
Miller’s Anatomy of the Dog14 
The gallbladder is a thin walled structure located in a fossa between the quadrate 
and right medial lobes of the liver. (Figure 2.1) The cranial end of the gallbladder is 
termed the fundus, the middle portion is the body, and the distal, narrower portion is the 
neck, which joins the cystic duct.14 The main function of the gallbladder is to store and 
concentrate bile.  The gallbladder also absorbs lipid-soluble compounds.14 The
gallbladder can accommodate a volume of approximately 1 milliliter per kilogram of 
body weight.17 The vagus nerve supplies the parasympathetic innervation to the 
gallbladder musculature causing it to contract and the duodenal sphincter to relax, 
allowing emptying.14, 18 The splanchnic nerves provide sympathetic innervation to the
gallbladder, allowing it to relax.18  Increased intra-abdominal pressure secondary to 
inspiration causes the majority of pressure changes within the gallbladder.14 The





    
   
 
    
  
 
   




    
   
 
   
  
 
   
  
   
  
distention and is a low pressure system.16 The left branch of the proper hepatic artery
provides the blood supply to the gallbladder and bile duct.14 The gallbladder is not an 
essential organ to the dog and is absent in some species including the horse and rat.15 
Bile is composed of bile acids or salts, bile pigments, cholesterol, lecithin, and 
inorganic salts.18 Bile acids are formed from cholesterol.19 Bile acids function to 
emulsify dietary lipids and to solubilize byproducts of fat digestion.19 They are produced 
in the smooth endoplasmic reticulum of the hepatocytes, and as they are secreted, break 
down phospholipids and cholesterol from the cell membrane.19 Phospholipids, 
cholesterol, and bile acids all form the functional component of bile, which is key in the
digestion and absorption of fats.19, 20 Bile acids also stimulate the release of intestinal 
lipases that are responsible for absorption of fat soluble vitamins such as vitamin D.18 
Bile pigments are another component of bile, with bilirubin being the main bile
pigment, giving bile its characteristic green color.19 Bile pigments do not aid in digestive
function but facilitate excretion of waste products.19 Bilirubin is produced during
enzymatic cleavage of hemoglobin from normal red blood cells and is derived from the
degradation of heme moiety.16, 19-21 Heme is enzymatically cleaved by heme oxygenase
and forms biliverdin, which is then reduced to bilirubin by biliverdin reductase.21 
Bilirubin is hydrophobic, meaning that it can only be transported in the blood when it is 
bound to albumin.21 Unconjugated bilirubin is soluble in plasma due to its strong affinity
for albumin.16 Once conjugated, bilirubin is excreted into the bile.  In the small intestine, 
conjugated bilirubin is converted to urobilinogen which is then excreted in the feces.21 








   








   
 
   
  
When fat is ingested and reaches the duodenum, discrete endocrine cells in the
gastrointestinal tract are stimulated to release cholecystokinin, which stimulates 
contraction of the gallbladder and relaxes the sphincter surrounding the bile duct at the 
opening of the major duodenal papilla (this sphincter is referred to the Sphincter of Oddi
in some veterinary texts) allowing stored bile from the gallbladder to flow into the
duodenum.1, 18, 19 Bile acids are then absorbed by the ileum and transported via the portal 
vein back to the liver where they are absorbed by the hepatocytes.19 This circulatory flow
of bile from the liver to intestine to portal blood and back to the liver and intestines is
termed enterohepatic circulation.19, 20 This positive feedback system is initiated through 
gallbladder contraction and thus initiates additional bile synthesis by the hepatocytes.19, 20 
This feedback system is important as bile is composed of 90% recirculated bile salts, 
which are necessary for lipid absorption from the small intestine.18 
Hepatobiliary Disease
There are many disease processes that can affect the hepatobiliary system. 
Clinical signs associated with these diseases are often nonspecific but can include 
lethargy, vomiting, diarrhea, pyrexia, anorexia, icterus, abdominal pain, or ascites.1, 17, 18, 
22 Physical examination findings can also be nonspecific but may reveal icteric mucus 
membranes, a painful abdomen, or pyrexia.  Pain may be localized to the cranial 
abdomen on the right side if the patient has biliary disease secondary to pancreatitis or 
pancreatic neoplasia.18 Common abnormalities seen on a complete blood count include a
stress leukogram or a neutrophilic leukocytosis with a left shift, which is most commonly
seen with rupture of the biliary tract, or non-regenerative anemia due to chronic disease.17 










   
  
 
   
   
  
 






   
 
aminotransferase (ALT), increased serum alkaline phosphatase (ALP), increased gamma-
glutamyl transpeptidase (GGT), hyperbilirubinemia, and hypercholesterolemia.  If the
patient is septic, hypoalbuminemia and hypoglycemia may also be seen.17 Patients with a 
biliary obstruction may have hyperbilirubinuria on urinalysis.  Clotting times can also be 
prolonged when absorption of fat soluble vitamin K is impaired, leading to reduced 
hepatic synthesis of vitamin K-dependent coagulation factors.1 Pre- and post-prandial 
bile acids are used to test liver function and can be abnormal due to liver failure or 
obstruction of the biliary system.  Pre- and post-ammonia challenge of blood ammonia 
levels are abnormal due to liver failure but are not affected by biliary disease.  
Obstructive diseases of the hepatobiliary system
Extrahepatic biliary obstruction can be caused by an obstruction of the cystic or
bile duct lumen, obstruction of the major duodenal papillae, or extraluminal compression 
of the cystic or bile duct.1 Some causes of extrahepatic biliary obstruction include
pancreatitis, neoplasia (including neoplasia of the gallbladder, bile ducts, pancreas, 
gastrointestinal tract, or lymph nodes), cholelithiasis, choledocholithiasis, cholecystitis, 
abscesses, granulomas, or fibrosis secondary to trauma.17, 18, 21, 23 Intraluminal
obstruction can be caused by cholelithiasis, biliary sludge or gallbladder mucocele, or 
parasitic infections.1, 17, 24 
Pancreatic disease is the most common cause of extrahepatic biliary obstruction in 
dogs.21, 24 Pancreatitis is an inflammatory condition of the pancreas that can result in 
inflamed tissues, abscesses, or cysts that can cause compression of the adjacent bile duct.  
It can also cause scar tissue to form in or around the bile duct.21 Ultrasound is used most





   
   
 
   
   
 
 
   
  
   
   
    
     
  




   
  
to pancreatitis.  Following obstruction, dilated cystic and bile ducts are seen initially
followed by the extrahepatic ducts and then intrahepatic ducts.  It takes 5 to7 days post-
obstruction to see dilated intrahepatic ducts.25 Treatment of the obstruction usually
consists of medically managing the pancreatitis.  Early detection and management of 
pancreatic abscesses or necrosis has been shown to improve survival.26 In severe or 
chronic cases, surgical intervention, such as cholecystoduodenostomy, cholecysostomy,
cholecystectomy, or cholecystojejunostomy, may be needed.18, 26, 27 Mortality rates in 
dogs that undergo biliary tract surgery range from 50% to 100%.26, 27 Pancreatic
neoplasia, such as pancreatic adenocarcinoma, can also cause an extrahepatic obstruction 
of the bile ducts.  Treatment is often unrewarding, as most pancreatic neoplasms are
malignant, and the prognosis is generally poor.21 Pancreatic abscesses, cysts, and 
granulomas are less common causes of biliary obstruction.18, 21 
Primary hepatobiliary tumors are rare and account for 0.6% to 1.5% of all canine 
neoplasms.17, 28 The two types of primary bilious tumors are biliary cystadenoma and 
biliary adenocarcinoma.  17, 28 Biliary cystadenomas occur most frequently in older cats 
and are rare in the dog.17 They are typically located in the intrahepatic bile ducts and can 
be single or multifocal and involve one or more hepatic lobes.17 Biliary carcinomas 
account for 22% to 41% of all malignant liver tumors in the canine.28 They most
commonly occur in the intrahepatic ducts and very rarely occur in the gallbladder itself.17, 
28  Biliary carcinomas are slow growing tumors and are initially locally aggressive.  
Biliary carcinomas are often advanced or metastasized at the time of diagnosis due to a
lack of clinical signs early in the course of disease.17 Ultrasound is the most common 




   
 
  




   
 






     
 
    
  
to obtain a definitive diagnosis.17 Treatment of hepatobiliary tumors is determined by the 
type of tumor and its location.
Cholelithiasis, or stone formation in the gallbladder, is one of the more recognized 
diseases of the gallbladder, although it still occurs rather infrequently in dogs and the
etiology is unknown.17, 23 It occurs most frequently in miniature schnauzers and 
miniature poodles.17 It has also been shown that older female dogs are predisposed to 
cholelithiasis.17 Choleliths vary in size and composition, with cholesterol, bilirubin, and 
calcium all being reported as components of stones.17, 18, 23 Abnormalities that may lead 
to cholelithiasis include gallbladder dyskinesia, hypercholesterolemia, 
hypertriglyceridemia, hyperbilirubinemia, endocrine disease, and transport defects in the 
gallbladder.17 
Choleliths can cause an obstruction of the biliary tract or inflammation of the liver 
or biliary tract that can eventually lead to gallbladder or biliary rupture and subsequent
bile peritonitis.18 Many times, however, choleliths are found incidentally in dogs at the
time of necropsy.  Choledocholithiasis occurs when stones form in the bile duct.  These
stones are either primary or secondary, with primary stones developing in the bile duct 
and secondary stones developing in the gallbladder and later passing into the bile duct.  A 
definitive diagnosis of cholelithiasis or choledocholithiasis is usually made with 
abdominal ultrasound.  Treatment for cholelithiasis and choledocholithiasis depends on 
the severity of clinical signs.  Most patients with stones are asymptomatic. 17 Medical 
therapy consists of dissolution of the stones or providing supportive care until the
stone(s) pass.17 If the stones are causing complete obstruction, surgical intervention is 











      









   
    
A gallbladder mucocele is defined as an abnormal accumulation of inspissated 
mucus that causes distention of the gallbladder.26, 29-31 As the mucocele expands, it 
stretches the gallbladder wall and disrupts the flow of bile leading to pressure necrosis of 
the wall.17 Gallbladder mucoceles are characterized histologically by hyperplasia of 
mucus-secreting cells in the gallbladder mucosa, and it has been suggested that the 
mucocele results from dysfunction of these cells.32, 33 The exact cause of this dysfunction 
is unknown, but it is thought to be multifactorial.32 
Factors that have been shown to predispose dogs to mucoceles include 
dyslipidemias, decreased motility of the gallbladder, endocrine diseases, such as 
hyperadrenocorticism and hypothyroidism, and exogenous steroid administration.17, 30, 
34,33, 35 It has also been shown that extrahepatic biliary obstruction does not play a
primary role in the formation of gallbladder mucoceles in dogs as it does in humans.32 
Older patients are more likely to form a mucocele with the median age being 10 years.17 
Medium-sized breeds are most commonly affected, particularly the cocker spaniel, 
Shetland sheepdog, and miniature schnauzer.30, 32, 33 Complications associated with 
gallbladder mucoceles include bile peritonitis secondary to rupture, extrahepatic bile duct 
obstruction, cholecystitis, necrotizing cholecystitis, and pancreatitis.17, 22 
The diagnosis of a gallbladder mucocele is most often made with ultrasound, due
to its characteristic kiwi-like appearance.17, 33 Findings on ultrasound that have been 
shown to correlate with a gallbladder rupture include discontinuity of the gallbladder 
wall, hyperechoic fat in the cranial abdomen, free abdominal fluid, and striated, 
echogenic material located outside of the gallbladder lumen.22, 32, 33 The sensitivity for




   
    








   
  
  
    
  
 
    
study of 45 dogs that evaluated ultrasonographic findings associated with gallbladder 
rupture, ultrasound was shown to have a specificity of 44.4% for identifying gallbladder 
rupture.22 This may be due to the fact that it can be difficult to detect a rent in the
gallbladder wall in the absence of an extruding mucocele or mucocele free in the 
peritoneal cavity.22 A clinical challenge with the imaging modalities currently available
is determining whether or not surgical therapy of a gallbladder mucocele is warranted 
when a rent in the gallbladder wall is not definitively identified with ultrasound.
Nonobstructive diseases of the hepatobiliary system
Nonobstructive diseases of the hepatobiliary tract include cholecystitis, 
necrotizing cholecystitis, bacterial cholangiohepatitis/cholangitis, emphysematous 
cholecystitis, choleliths, parasites, neoplasia, or congenital anomalies.17 Several of these
disease processes can eventually lead to biliary obstruction.  
Cholecystitis is inflammation of the gallbladder and bile ducts.  It is commonly
caused by migration of bacteria from the small intestine through the bile duct or by
hematogenous spread of bacteria.17 Factors that can predispose to cholecystitis include
cholelithiasis, gallbladder mucoceles, bile stasis, ascending biliary tract infection, or
biliary neoplasia.17, 23 Clinical signs associated with cholecystitis can include anorexia, 
vomiting, abdominal pain, and fever.17 Laboratory findings are variable. Ultrasound is 
considered the gold standard in dogs for diagnosing cholecystitis.17 Treatment of 
cholecystitis depends on the severity of the disease but usually consists of medical or 
surgical management.  
Necrotizing cholecystitis occurs when a bacterial infection causes necrosis of the 







   
 
  
     
 
  





    
   
   
   
 
Three classes of necrotizing cholecystitis have been described.  Class I includes
necrotizing cholecystitis without gallbladder rupture.17 Class II occurs with acute 
necrotizing cholecystitis with gallbladder rupture and bile peritonitis, and Class III
includes chronic cholecystitis with cholecystic and omental adhesions with or without
fistulas.17 
Bacterial cholangitis and cholangiohepatitis occur when infection from the biliary
tree ascends into the liver. These conditions occur more frequently in cats than in dogs.36-
38 Shetland sheepdogs have a higher incidence of these diseases than other dog breeds.17 
Infection usually occurs secondary to other circumstances including patients receiving
immunosuppressive therapy, patients with hyperadrenocorticism or diabetes mellitus, 
biliary stasis, septicemia, decreased hepatic blood supply, or necrosis of hepatic tissue.23 
Bacterial cholangitis and cholangiohepatitis are rarely reported in dogs.38 Diagnostic 
imaging with cholangitis and cholangiohepatitis usually consists of abdominal 
radiography and ultrasound and is often non-specific.38 
Emphysematous cystitis occurs when gas-producing bacteria infiltrate the
gallbladder and cause gas to fill the gallbladder lumen or invade the gallbladder wall.  It 
is typically associated with animals with diabetes mellitus but can be seen in any
animal.17 This condition can be diagnosed using radiography or ultrasound.  On 
radiographs, a round to ovoid gas opacity structure may be seen superimposed over the
liver in the cranioventral portion of the abdomen.17 Ultrasound displays a gas interface in 
the area of the gallbladder with distal acoustic shadowing.17 Surgical intervention is the 




    
 
    
 















   
  
Biliary parasites are rare and are more commonly seen in cats than in dogs.18 
Biliary trematodes, such as Platynosomum concinnum, can cause a partial or complete 
obstruction of the biliary tract or secondary cirrhosis and hepatic lipidosis.1, 18 
Hepatobiliary disease associated with trematode infection has been primarily recognized 
in Florida and Hawaii.18 Clinical signs of  biliary parasites depends on the degree of liver 
injury and biliary obstruction but can include weight loss, vomiting, or anorexia.17 
Eosinophilia may be present on a complete blood count and elevated liver values can be
seen on the serum chemistry panel.17 Abdominal radiographs are usually normal, and 
abdominal ultrasound demonstrates dilated bile ducts if the patient is obstructed.  A
definitive diagnosis can be reached by aspirating and performing cytology on the bile or
by performing a biopsy of the liver.17 
Current Modalities Available for Imaging the Hepatobiliary System
Diagnostic imaging is an integral part in the diagnosis of hepatobiliary diseases.  
Modalities available for imaging of the hepatobiliary system include radiography, 
ultrasonography, computed tomography, magnetic resonance imaging, and nuclear 
scintigraphy.  Positive contrast agents used with several of these imaging modalities can 
also be very useful in diagnosing hepatobiliary disease.  Some examples of these studies 
include cholangiography combined with radiography, endoscopic retrograde
cholangiopancreatography, and percutaneous transhepatic cholangiography.  Magnetic
resonance cholangiopancreatography is also a very useful imaging technique that does 
not require the use of contrast media.  Many of these techniques have been used in 
humans for quite some time now and are being or have been adapted for use in 








   
 
  
   




   
 
 
   
  
treat biliary disease.17 Each modality or technique has its own advantages and 
disadvantages.
Radiography
Abdominal radiography is widely available and is recommended in dogs 
suspected of having hepatobiliary disease.  However, radiography is a fairly insensitive 
method of diagnosing hepatobiliary disease.36 Radiography also exposes the patient to 
ionizing radiation.  Radiographic signs associated with hepatobiliary disease can include
but are not limited to masses or irregular liver margins, hepatomegaly, decreased serosal 
detail secondary to peritoneal effusion, radiopaque choleliths or choledocholiths, 
emphysema of the gallbladder or gallbladder wall or mineralization of the gallbladder 
wall.17, 39 Most biliary stones do not contain sufficient calcium to be seen
radiographically.17 
Ultrasonography
Ultrasound allows for a detailed examination of the architecture of the
hepatobiliary system including the liver, gallbladder, bile ducts, and hepatic vasculature.  
It is widely used and available, non-invasive, and is currently considered the diagnostic 
modality of choice when looking for causes of hepatobiliary disease in small animals.17 
Common ultrasonographic findings associated with biliary disease include
choleliths/choledocholiths, thickening of the gallbladder wall, gallbladder sludge or 
mucocele, biliary tree dilation or obstruction, or pericholocystic fluid.17, 39 
One disadvantage of ultrasound is that it provides inferior images of the




   
  








   
    
   
    
   
   
  
  
with other modalities.2-4, 6 Dilation of the bile ducts may be evident as early as 24 to 48 
hours following obstruction.16, 29 Intrahepatic duct dilation may be identified with 
ultrasound 5 to 7 days following complete obstruction.16, 29 Gas in the gastrointestinal 
tract can also limit ultrasonographic evaluation of biliary structures in some dogs.  Mild
structural abnormalities or functional disturbances may not be detected with ultrasound.2 
Ultrasound also has a low sensitivity and specificity for diagnosing inflammatory
conditions such as cholangitis and pancreatitis, where ultrasound findings have been 
shown to correlate poorly with the histological diagnosis.37 
Computed tomography (CT)
The gallbladder is readily seen on an abdominal CT with and without the use of 
non-biliary specific iodinated contrast due to its shape and density.  The size and location 
of the gallbladder can vary depending on the amount of bile present within the
gallbladder lumen.40 The gallbladder wall is not typically seen as a distinct structure
from the gallbladder contents because the wall and contents are the same density. The
bile ducts are not seen on CT unless they are dilated due to obstruction or contain mineral 
dense calculi.40 Dilated bile ducts are characterized as tortuous, non-enhancing tubular 
structures that are hypodense (dark) to surrounding parenchyma.40 Mineral dense calculi
can be seen in the gallbladder or bile ducts on CT. Non-biliary specific iodinated contrast 
does not cause enhancement of the gallbladder or bile ducts.  Modern CT scanners along
with the use of a biliary-specific iodinated contrast can provide high quality images of the
biliary system.  This topic along with the topic of CT will be discussed in greater detail 








    
    










   
   
  
    
  
 
Magnetic resonance imaging (MRI)
The use of MRI as a diagnostic tool in veterinary medicine has increased over the
past few years.  Its high contrast resolution allows soft tissue pathology to be
characterized very sensitively due to its detection of subtle shifts in cellular water and
protons.37, 39 MRI allows for detection of inflammatory processes of the hepatobiliary
system and pancreas due to changes in signal intensity as well as contrast enhancement.37 
The gallbladder is seen on MRI as a discrete, semicircular T2 hyperintense structure.41 
On a T2 weighted sequence, fluids are bright when compared to surrounding tissues.  The
gallbladder is fluid filled (bile), which allows it be clearly seen on this sequence.  
Hyperintense means that a structure is brighter than its surrounding tissues, and 
hypointense means that it is darker than surrounding tissues.  The bile ducts may be
evaluated by using various imaging planes, such as transverse, sagittal, or dorsal planes.41 
A disadvantage of MRI is its long data acquisition time, which leads to prolonged
anesthetic episodes in small animals.  MRI provides only morphological information 
without any functional information.  It is also costly with limited availability.
Nuclear scintigraphy
Hepatobiliary scintigraphy is used most often in dogs for diagnosing biliary
obstructions that cannot be confirmed by ultrasound.1, 42 It involves the intravenous
injection of a radiolabeled isotope, most commonly technetium-labeled iminodiacetic
acid analogues (99mTc-IDA), followed by scintigraphic imaging with a gamma camera
over the course of three hours to determine if the isotope is taken up by the liver, excreted 
into the biliary tract, or expelled into the intestines.42, 43 In a normal canine patient, 




   





   













isotope administration.1, 42 If it is not observed in the intestines within three hours, a
diagnosis of a complete extrahepatic biliary obstruction can be made.1, 42 Imaging may
be extended beyond three hours, and delayed imaging (24 to 48 hours) is recommended
to confirm lack of intestinal activity.1, 42 Other scintigraphic findings seen with a 
complete chronic biliary obstruction include a subnormal hepatic extraction fraction (the
portion of isotope removed from the plasma as it circulates through the liver), a
prolonged clearance half-life ( the time it takes for half of the isotope to be excreted from 
the hepatocytes into the biliary tract), and an inability to see the biliary tree.42 Partial 
extrahepatic biliary obstructions are characterized by normal hepatic extraction fractions 
and prolonged clearance half-life and cannot be ruled out or confirmed on the basis of 
radioactivity in the intestines.42 
Hepatobiliary scintigraphy is non-invasive and sensitive in diagnosing biliary
obstruction.1 However, the need for radioisotopes and expensive equipment has limited 
the availability of this modality to mainly select referral institutions.  Due to the low 
resolution of scintigraphy, identification of the level of the biliary obstruction is not
always possible, and the technique does expose the operator to ionizing radiation.1 Also, 
there are short term restrictions on patient handling following administration of 
radioisotopes that can further delay surgery if needed.1 Scintigraphy also exposes the 
patient to ionizing radiation.
Conventional cholangiography
Contrast agents are used in veterinary medicine to improve the visibility of certain 
anatomic structures.  The two types of radiographic contrast used are positive and 













   
   







be more opaque than surrounding tissues on radiographs.  Negative contrast agents are
gases that have a lower density causing them to be radiolucent.  The two main types of 
positive contrast agents used in human and veterinary medicine are barium and iodine.  
Barium is used primarily in studies of the gastrointestinal tract.  Iodinated contrast agents 
are used for many types of studies including myelography, urogenital studies, and 
vascular studies.  Most standard iodinated contrast agents are administered intravenously
and are excreted renally through glomerular filtration due to the fact that they are water
soluble and not heavily protein bound.  Biliary specific iodinated contrast agents are
transported in the blood bound to albumin and are taken up specifically by the 
hepatocytes.44 It is excreted in the same fashion as bile, through the bile ducts and into 
the small intestine.  Biliary specific contrast agents cause the liver, gallbladder, and bile
ducts to opacify.  A small amount of biliary contrast is excreted renally.44 
Cholangiography combines radiography with the use of an oral or intravenous
biliary specific iodinated contrast.  Cholangiography has been used in combination with 
conventional radiography in dogs over the years, and it provides good opacification of the 
gallbladder and bile ducts in most patients.45 In some patients, nonopacification of the 
gallbladder occurs for no apparent reason.45 In others, causes of nonopacification of the 
gallbladder in patients that are properly prepared (fasted for 12 hours prior to the study)
and given a sufficient dose of contrast include vomiting of the oral contrast or 
subcutaneous injection of an intravenous contrast agent, gastrointestinal disorders 
preventing proper absorption of oral contrast agents, hepatic dysfunction causing
decreased excretion of contrast material into bile, hyperbilirubinemia, or disorders of the 










   
   
   
 
   
 
   
  
    
   
 
 
   
  
sectional imaging modalities (CT and MRI) and other interventional techniques, 
conventional cholangiography is seldom used today in humans or animals.12 
Endoscopic retrograde cholangiopancreatography (ERCP)
Endoscopic retrograde cholangiopancreatography (ERCP) combines the use of 
endoscopy, fluoroscopy, and iodinated contrast media to image the biliary and pancreatic
duct systems.3, 7 It is performed by passing an endoscope into the duodenum, locating the 
major duodenal papilla, and then passing a catheter filled with iodinated contrast media 
into the papilla.2 The contrast media is then injected into the papilla until the bile ducts 
and the gallbladder are completely filled.2 This procedure is repeated with the accessory
pancreatic duct by way of the minor duodenal papilla.2 Fluoroscopy allows for 
visualization of the catheter as well as visualization of the bile ducts and gallbladder once
they are opacified with contrast.
In the past, ERCP was considered the gold standard in humans for diagnosing
hepatobiliary disease.6, 46, 47 However, in some institutions, magnetic resonance
cholangiopancreatography has become the initial diagnostic imaging tool, with ERCP
being reserved for therapeutic intervention.6, 46, 47 ERCP has been performed in healthy
dogs and cats and in dogs with chronic gastrointestinal problems.2, 3, 7 Due to its high 
resolution, ERCP provides excellent delineation of the bile ducts and can also be used for
therapeutic treatment, although, it has been described as technically difficult in small
animals.2, 6, 7 Disadvantages of ERCP are that it is very invasive to the patient
(complication rates up to 5% in humans), exposes the patient to ionizing radiation, is 











    





   
    
   
  
   
    
  
 
   
Percutaneous transhepatic cholangiography (PTC)
Percutaneous transhepatic cholangiography (PTC) is a technique involving
ultrasound guided injection of iodinated contrast directly into the gallbladder, which 
allows for direct visualization of the gallbladder and biliary tract.1 Abdominal 
radiographs are obtained immediately, at 45 minutes, 2 hours, and 24 hours after 
injection.1 Opacification of the gallbladder and bile ducts as well as the duodenum 
usually indicates patency.  However, high pressure from contrast injection could falsely
generate patency in obstructed patients.1 PTC has a high sensitivity and specificity for
diagnosing biliary obstruction in dogs.1 However, because this technique is invasive with 
potential complications including bile peritonitis, gallbladder rupture, or hepatic
hemorrhage, it is not often used in clinical patients.1 
Magnetic resonance cholangiopancreatography (MRCP)
Magnetic resonance cholangiopancreatography (MRCP) is a well recognized 
technique in humans for examining the biliary and pancreatic systems.33 It has also been 
demonstrated in cats.6, 25 MRCP is noninvasive and provides a detailed map of the biliary
tree and pancreatic duct without the use of ionizing radiation or contrast media.6, 25 Slow 
moving fluids, such as bile, are hyperintense (bright) on heavily T2 weighted sequences, 
allowing them to be easily seen against the hypointense (dark) background of 
surrounding tissues.6, 25, 34 It has been shown to provide accurate detail of biliary calculi, 
malignant obstructions, variants in biliary anatomy, and post-surgical alterations of the
biliary tract in humans.34 MRCP combined with conventional MR sequences provides 





    
  
 










   




   
The goal of MRCP is to generate images that resemble those obtained in more invasive
procedures, such as endoscopic retrograde cholangiopancreatography.29 
Some disadvantages of MRCP are that it can be costly and has limited 
availability.  It also requires prolonged anesthetic times in small animals.  MRCP can be
prone to artifact and provides little information on biliary kinetics and function.7 MRCP
can also be inconclusive if air is present in the biliary system following surgery.48 
Multi-Slice Computed Tomographic Cholangiography (MSCTC)
Over the past 40 years, CT scanners, and their imaging capabilities and image
quality have improved tremendously.49 Due to this improvement, the use of CT in 
clinical practice has experienced enormous growth.49 CT allows for sectional or slice-
oriented imaging of a patient, making anatomic localization of abnormalities more
accurate than with conventional radiography.39 CT also has excellent contrast resolution, 
which refers to the ability to discriminate different tissues composed of different 
substances and display them with different shades of gray or brightness in an image. 39 
Single-slice versus multi-slice or multi-detector CT scanners
Four generations of CT scanners have been described in the literature.  The first 
generation scanner only scanned the head and used a pencil-like x-ray beam and a single 
detector.49, 50 The tube detector movements were linear and rotary, which was termed 
“translate-rotate motion.”49, 50 A typical CT scan with this scanner took 25-30 minutes 
and only provided a single slice of data.50 The second generation scanner employed the 
same “translate-rotate motion” but increased the rate of acquisition time by incorporating





   
  
 
    
 









   
  
   
acquired in a shorter amount of time. In the 1970s, a third generation scanner was 
introduced that completely eliminated the translate motion and employed a “rotate-rotate”
motion.50 This meant the both the x-ray tube and the detectors rotated around the patient, 
which led to much shorter acquisition times.  The third generation scanner is still the
most widely used CT scanner today.49, 50 Fourth generation scanners were mainly
designed to combat an artifact produced by the third generation scanners called “ring
artifact.”49 Ring artifact occurs when the CT detectors are not properly calibrated with 
one another.49 When this happens, the detectors record incorrect data in every projection 
leading to this information being reconstructed as a ring on the image.50 This ring makes 
it difficult to see the underlying anatomy on the image.  The fourth generation scanner 
employs the “rotate-stationary” movement, which consists of a rotating x-ray tube but a 
stationary detector array.49 These scanners are significantly more costly than the third 
generation scanners and more difficult to maintain, and algorithms have now been 
developed to combat the ring artifact in the third generation scanners, negating the need 
for a fourth generation scanner.49 
Most single slice and all multi-slice CT scanners are third generation scanners.51 
The primary difference between single slice and multi-slice scanners is the design of the
detector arrays.51 Single-slice detector arrays are one dimensional and consist of a large
number (usually >750) of detector elements that are in a single row across the irradiated 
slice to intercept the x-ray.51 With multi-slice CT, each single-slice detector element is 
divided into small detector elements that form a two-dimensional array and multiple 








   















simultaneously with multi-slice CT scanners depends on the number of detectors.  This 
number ranges from a 4-slice scanner to a 64-slice scanner.  
Another difference between single and multi-slice scanners is the relationship 
between slice thickness and x-ray beam width.51 With single-slice CT, the slice thickness 
is pre-determined by the x-ray beam collimation design.51 In the slice thickness 
direction, the detectors are monolithic, meaning that the single elements are long enough 
to intercept the entire x-ray fanbeam width.51 Multi-slice CT slice thickness, however, is 
determined by the width of the detector rather than the x-ray beam collimation.51 This 
means that multi-slice CT scanners can acquire much thinner slices than single-slice CT
scanners, which in turn, allows for generation of high quality three-dimensional
reconstructions.51 When imaging the biliary system, conventional or single-slice CT, is 
often inadequate for evaluating the biliary tract or detecting low density calculi because
its resolution, or image detail, is inferior for demonstrating smaller structures like the bile 
ducts.52 Multi-slice CT is superior in that it allows for rapid acquisition of large data sets 
and has high spatial resolution (greater ability to discern small objects adjacent to each 
other).9, 52, 53 
Multi-slice computed tomographic cholangiography (MSCTC)
The high diagnostic accuracy of MSCT in human medicine has been 
demonstrated in the fields of thoracic, cardiac, and cardiovascular imaging.9 MSCT has 
also been shown to be valuable in veterinary medicine in regards to the adrenal glands, 
hepatic portal vasculature, and intestines.10 The combination of multi-slice CT with 
cholangiography has also been shown to be very helpful in the diagnosis of hepatobiliary




    




   
   
  
  
     






    
  
  
human medicine.48, 52, 54-61 Multi-slice CT cholangiography (MSCTC) is non-invasive
and involves intravenous administration of a biliary specific contrast agent followed by
MSCT imaging, which is then usually re-formatted into two-dimensional and three-
dimensional reconstructions.  The most common reconstructions used include maximum 
intensity projections (MIP), shaded surface display (SSD), and multiplanar
reconstructions (MPR). MIPs are commonly used in human medicine for three
dimensional reconstruction of CT angiograms because they allow for separation of high 
attenuation enhancing vessels from lower density surrounding soft tissue structures.62 In 
relation to the bile ducts, MIPs are good at detecting intraluminal calculi because they
allow contrast-filled structures to be evaluated in relation to densities of other
surrounding structures.56 SSDs provide a realistic three-dimensional reconstruction of
the surface of structures while obscuring intraluminal structures.56 SSDS are used in 
human imaging primarily for evaluating for vascular disease, such as aneurysms.  MPRs
are created by combining a series of successive transverse images and formatting them 
into a larger image in a different orientation, such  as a sagittal or dorsal plane.63 This 
type of reconstruction provides a two-dimensional reconstruction of a specific area of the
body which helps to enhance the viewing of the complete anatomic picture.56 
MSCTC also provides functional information regarding hepatocyte excretion, and 
if it is normal, provides detailed images of the bile ducts, including the intrahepatic
ducts.12 In post-cholecystectomy human patients, MSCTC can allow differentiation
between normal post-surgical dilation and pathologic biliary obstruction.8 In non-
obstructed post-cholecystectomy patients, contrast material should be seen in the 




   
    
 






   
  










functional or anatomical abnormalities.8 In humans, when compared to MR
cholangiography, CTC is better for determining the degree of biliary obstruction.8 MR
cholangiography may show dilation of the bile ducts in an obstruction but will not
differentiate between a complete versus a partial obstruction.8 With CTC, in cases of 
complete obstruction, there will be a lack of enhancement of the dilated intrahepatic ducts 
and liver parenchyma.8 
As with most imaging modalities, MSCTC does have some disadvantages. 
MSCTC exposes the patient to ionizing radiation.  There may be side effects associated 
with iodinated contrast material, although they are rarely reported in humans and dogs
and are usually mild.12, 64, 65 The side effects will be discussed in further detail under the
heading biliary contrast media.  Humans and dogs with poor hepatobiliary function, 
specifically conditions associated with elevated plasma bilirubin, have unreliable 
excretion of biliary contrast, which can lead to non-diagnostic or poor quality CT
cholangiography studies.1, 12, 48, 54, 66-70 In humans, a serum bilirubin of greater than 
2.0mg/deciliters (dL) is a good predictor of poor contrast excretion.12, 68, 69 However, 
even in hyperbilirubinemic patients it has been shown that although the biliary tract is not
optimally enhanced, it is still possible to obtain a diagnostic CTC study to detect 
abnormalities such as dilation or obstruction of the bile ducts.48, 68 Other studies in 
humans have shown that slowly infusing a biliary specific contrast agent over several 
hours as opposed to a single intravenous injection may allow for increased density of the
bile ducts in patients with high bilirubin levels (greater than 1.1mg/dL).48, 69 Good 
contrast enhancement of the biliary tree can also be obtained by increasing the dose of 



















and then waiting 2-2.5 hours after contrast administration to perform the CT scan.54 
Several studies evaluating the effect of bilirubin on biliary iodipamide (Cholografin®) 
excretion in dogs suggest that the contrast dose should be increased in hyperbilirubinemic 
patients in order to obtain adequate opacification of the biliary structures, and that a
prolonged infusion or decrease in contrast dose is not indicated.66, 67, 71 Although there
has been mixed success with MSCTC in human patients with bilirubin levels greater than 
2 mg/dL, several studies have shown that diagnostic studies could be performed in some
patients with bilirubin levels as high as 9.3mg/dL.48, 54, 68, 69 To the author’s knowledge, 
no studies have been performed using MSCTC in dogs with hyperbilirubinemia. 
Indications for performing MSCTC in humans include 
cholelithiasis/choledocholithiasis, anomalous conditions of the bile ducts, unexplained 
upper abdominal pain, dilation of biliary ducts on ultrasound, neoplasia of the liver, 
biliary tract, and associated structures, biliary tract rupture and stricture, and pre-and 
post-surgical planning.5, 6,8,11,13 Indications for imaging the canine biliary tract are similar 
and include but are not limited to cholelithiasis or choledocholithiasis, cholecystitis, 
gallbladder mucoceles, neoplasia of the liver and/or biliary tract, or extra-hepatic biliary
tract rupture or obstruction.1-4 Many of these diseases are only accurately characterized 
in advanced stages or at post-mortem due to the fact that clinical signs are often absent or 
non-specific early in the disease process.  Earlier diagnosis of these diseases is important, 
and a sensitive, non-invasive method for imaging the biliary tract and determining biliary





   
  
   
  




   
    
  
  
     




Biliary Contrast Media 
The use of cholangiography in the dog came about in the 1920s when halogenated 
phthaleins were discovered.45 It was found that these compounds were excreted 
primarily by the hepatocytes and were concentrated up to eight to ten fold in the
gallbladder.45 These contrast agents were given orally or intravenously and produced 
good opacification of the gallbladder but not the bile duct on radiographs.12,72 In the 
1940s and 1950s, several biliary specific contrast agents were introduced in Germany
including iodoalphionic acid and sodium iodipamide, which greatly improved the quality
of the cholecystogram and increased the safety of the technique.12 Iodipamide 
methylglucamine became available in 1955 in the United States and is still in use today
under the trade name Cholografin®, and is the only FDA approved biliary specific
contrast agent available in the United States.12 In the 1970s, other biliary specific
contrast agents were developed including meglumine iotroxate or  Biliscopin®.12 Several 
studies have been performed over the years comparing some of the different biliary
contrast agents.65, 73 The major difference between biliary specific iodinated contrast 
agents and standard iodinated contrast agents is their method of excretion.  Standard 
contrast agents are primarily renally excreted while biliary agents are absorbed by the
hepatocytes, excreted through the bile into the intestines, and eliminated in feces.
Standard iodinated contrast agents highlight the vascular system and the kidneys, while 
















   
  
  
Figure 2.4 Standard Iodinated Contrast versus Biliary Specific Iodinated Contrast 
Opacification of the gallbladder, cystic duct, bile duct, and intrahepatic ducts with biliary
specific contrast media
Iodipamide meglumine (Cholografin®)
Cholografin® is a biliary specific iodinated contrast agent used for intravenous 
cholangiography and cholecystography.  The chemical makeup of Cholografin® includes 





   
   
   
 
  
   
 
  
    
 
 
   






Cholografin® contains 520 milligrams (mg) iodipamide meglumine, 0.91mg sodium, and 
257mg organically bound iodine.75 When administered intravenously, Cholografin® is 
carried to the liver and rapidly secreted.  Based on studies in people, it should appear in 
the bile within 10 to 15 minutes following injection allowing for visualization of the 
hepatic and bile ducts.75 The biliary ducts should be visible 25 minutes following
injection with maximum filling reached by 2 to 2 ½ hours.75 Ninety percent of the 
contrast is eliminated through the feces without passing through the enterohepatic
circulation.75 The remaining ten percent of the intravenous dose is excreted through the 
kidneys.75 Cholografin® is indicated in humans for intravenous cholangiography in acute 
abdominal conditions, in patients with symptoms following cholecystectomy and in 
patients unable to take oral contrast media or absorb contrast media from the
gastrointestinal tract.75 Cholografin® is contraindicated in patients who are dehydrated, 
who have a hypersensitivity to salts of iodipamide, or who exhibit sensitivity when given 
a test dose or in patients with severe liver or renal impairment.75 
The published dosing in humans is 20 mL for adults and 0.3 to 0.6 mL/kilogram
(kg) of body weight for infants and children.75 A standard dose for dogs has not yet been 
established, although 0.6mL/kg and 0.9mL/kg of Cholografin® have been shown to 
provide good opacification of the biliary system when used with conventional
radiography.45 
Adverse effects of Cholografin® reported in humans include mild transient 
symptoms following rapid injection such as restlessness, sensations of warmth, sneezing, 
perspiration, salivation, flushing, pressure in the upper abdomen, dizziness, nausea, 






     
    
   





   
 
  
     
    
  
   




injection is completed.75 Swollen eyelids, laryngospasm, respiratory difficulties, 
hypotension, tachycardia and cyanosis are rarely reported.75 Hypersensitivity reactions 
may also occur  and in very rare instances, anaphylactoid reactions may be seen.75 In one
study, 2,034 injections of Cholografin® were given intravenously during cholangiography
over an eight year period and no anaphylactoid reactions occurred.12 In the same study, it
was noted that the incidence of mild adverse reactions increased when the injection was 
give rapidly.12 Cholografin® has been administered to dogs in multiple studies with side 
effects rarely reported. 
As stated above, Cholografin® is the only biliary specific contrast agent available 
in the United States.  It has been used in multiple conventional radiography
cholangiography studies in dogs and cats.  
Meglumine iotroxate (Biliscopin®)
Biliscopin® is also a biliary specific iodinated contrast agent used for intravenous
cholangiography and cholecystography.  Each mL of Biliscopin® contains 105mg of 
meglumine iotroxate, 370mg sodium chloride, 10mg sodium calcium edetate, and 40mg
sodium bicarbonate.76 Each 100mL bottle of Biliscopin® contains 5 grams of iodine.76 
The chemical makeup of Biliscopin® is similar to Cholografin® in that it is a dimeric
molecule and contains two substituted benzoic acids linked by a polymethylene chain.65 
The only differences are that Biliscopin® has a longer polymethylene chain and oxygen 
has been incorporated into the link.65 Biliscopin® is excreted in the same manner as 
Cholografin® through the bile, and visualization of the bile ducts usually occurs in 
humans 30-60 minutes after administration.76 Biliscopin is labeled for infusion in 










    
    





    
  
 
Contraindications for administering Biliscopin® in humans are similar to those of 
Cholografin® and include dehydration, severe cardiovascular compromise, 
hypersensitivity to iodine-containing contrast media, thyrotoxicosis, severely impaired 
liver or kidney function, and monoclonal IgM gammopathy.76 Side effects associated 
with Biliscopin® in humans are also similar to Cholografin®. They are usually mild and 
transient and include hypersensitivity reactions, vomiting, nausea, abdominal pain, 
arrhythmias, respiratory distress, seizures, temporary acute renal failure, and 
anaphylactoid reactions.76 The overall reaction rate of Biliscopin® is low, with one study
reporting an adverse reaction rate of 1% out of 1,061 injections of Biliscopin®.12 Little
has been reported on the safety of Biliscopin® in dogs.  A study specifically testing the 
safety of Biliscopin® in cats showed it is safe to use in normal cats and that Biliscopin® 
produces the same contrast effect in cats as it does in humans.77 This study also stated 
that Biliscopin® is more favorable than other biliary contrast agents due to its rapid 
secretion into the bile, its effect on duct dilation, and because it is relatively non-toxic.77 
A study comparing different biliary contrast agents stated that Biliscopin® had a faster
















   
 
   
CHAPTER III
CHOLANGIOGRAPHY USING 64-MULTI-DETECTOR ROW COMPUTED
TOMOGRAPHY IN NORMAL DOGS
Introduction
Hepatobiliary diseases are often difficult to diagnose due to non-specific clinical 
signs that do not manifest until the late stages of disease.  Diagnostic imaging plays an 
important role in the diagnosis of these diseases.  Current imaging modalities and 
techniques available for biliary imaging in small animals include radiography,
ultrasonography, computed tomography, nuclear scintigraphy, cholangiography
combined with radiography, magnetic resonance cholangiopancreatography, endoscopic 
retrograde cholangiography, and percutaneous transhepatic cholangiography.3-6 
Radiography is often insensitive and non-specific for diagnosing hepatobiliary disease. 
Ultrasound is non-invasive and readily available but provides inferior images of the 
peripheral and intrahepatic bile ducts when compared with other modalities.2-4, 6 Gas in 
the gastrointestinal tract can limit ultrasonographic evaluation of biliary structures in 
some dogs.  Ultrasound is also user dependent and evaluating the biliary system requires 
a skilled ultrasonographer.  Nuclear scintigraphy is used in dogs for diagnosing biliary
obstructions.  It is non-invasive, but requires the use of expensive equipment and 
radioisotopes and has limited availability.  Commonly used advanced biliary imaging





   
   
    
  
    
  
    




   
 
     
     
   
   
endoscopic retrograde cholangiography (ERCP), which are considered the current gold 
standards.6, 48 Both of these techniques provide excellent visualization of the bile ducts, 
but are very invasive and costly.1-2, 6 In small animals, ERCP has also been reported to be 
technically demanding.3-5 Magnetic resonance cholangiopancreatography is widely used 
in human medicine for evaluating the hepatobiliary system.  It is non-invasive but can be
prone to artifact, provides no functional information, has limited availability, and is 
costly.1-2, 7 48
Multi-slice computed tomography (MSCT) enables rapid acquisition of
multiphase data sets that can be reconstructed into detailed three-dimensional images.2, 10
In veterinary medicine, MSCT has been shown to be valuable in evaluating abdominal 
structures.10, 78 This modality combined with cholangiography (intravenous injection of a
biliary specific contrast agent) allows for acquisition of high quality images of the biliary
system that can be reconstructed into three dimensional images.  These three-dimensional 
reconstructions have been helpful in humans in assessing for intraluminal calculi, biliary
obstructions, and ductal stenosis, due to the fact that they provide a more global and 
detailed view of the biliary anatomy.56 Multi-slice computed tomographic 
cholangiography (MSCTC) is non-invasive, provides information regarding biliary
kinetics and function, and has high spatial and contrast resolution.1-2, 7-10 MSCTC using a
64-slice scanner has been performed successfully in normal pigs but has not yet been 
reported in the dog.1
Indications for performing MSCTC in humans include but are not limited to
cholelithiasis or choledocholithiasis, anomalous conditions of the bile ducts, unexplained 




   
   
  
 







   
  
  
   
 
hepatobiliary structures, biliary tract rupture or stricture, and pre-and post-surgical 
planning .1,2,7,9-11 Indications for imaging the canine biliary tract are similar and include
but are not limited to cholelithiasis or choledocholithiasis, cholecystitis, gallbladder 
mucoceles, neoplasia of hepatobiliary structures, or extra-hepatic biliary tract rupture or 
obstruction.3-6 
The purposes of this study were to determine the feasibility of MSCTC in normal 
dogs and to describe the normal cross-sectional and three-dimensional biliary anatomy.  
Our goal was to demonstrate the best technique for performing high-resolution CTC with
regards to the type of contrast media used, contrast dose and optimal time to imaging
after injection of the contrast agent.
Materials and Methods
Sample population
The study population consisted of eight healthy adult purpose bred hounds and 
hound mixes.  The dogs were deemed healthy based on physical examination, complete 
blood counts, serum chemistry profiles, and urinalyses.  Ultrasound of the hepatobiliary
system was also performed on each animal by the author using a BioSound Esaote 
MyLab50a ultrasound machine and a microconvex probe with available frequencies 
ranging from 5-8 MHz as well as a linear probe with available frequencies ranging from 
7.5-12 MHz.  All procedures were approved by the Mississippi State University








   
   
 
      
   
 
  






   
   
Computed tomographic cholangiography
All dogs were fasted 12 hours prior to imaging to optimize image quality and to 
decrease the potential for complications associated with sedation.  Water was not
restricted.  An 18-22 gauge over the needle catheter was placed in the cephalic vein.  
Each dog was sedated with butorphanolb (0.2mg/kg intramuscular (IM) or intravenous 
(IV)) and dexmedetomidinec (5µg/kg IM or IV).  Sedation was re-dosed one time per dog
if needed.  Subjects were placed in dorsal recumbency for imaging and placed in the
gantry head first.  CTC was performed using a 64-slice, multi-row GE Lightspeed 
scannerd. The following scanning parameters were used for all CT imaging:  0.625 mm 
slice thickness, 0.5 seconds per rotation, 5 mm collimation, a pitch of 1, tube potential of 
120kV, and tube current of 300 mA. The imaging field of view extended from the apex
of the heart, caudally to the level of the left renal hilus.  Noncontrast images of the
abdomen were obtained prior to the administration of contrast.  
Cholografin®e (iodipamide meglumine) and Biliscopin®f (meglumine iotroxate)
were the biliary specific contrast agents used.  Two contrast groups were formed, with 
four dogs receiving Cholografin® and four dogs receiving Biliscopin®. Of the four dogs 
in each group, two were intravenously administered a contrast dose of 0.5mL/kg and two 
were intravenously administered 1mL/kg.  Each dog was scanned for sixty minutes at 0, 
5, 10, 15, 20, 30, 45, and 60 minutes. 
Image analysis
All CT images were reviewed on a designated picture archiving and 
communication system (PACS)g work station.  All images were evaluated for any





















reconstructions were performed, including multiplanar reconstructions (MPR), maximum 
intensity projections (MIP), and shaded surface display (SSD).  These images were
evaluated to determine which reconstructions provided the most useful information.  The
presence or absence of contrast in the lumen of the duodenum was also noted.  If contrast 
was present in the lumen of the duodenum, the time it was initially seen following
contrast administration was noted .Visibility scores were assigned to each biliary
structure including the dorsal and ventral portions of the gallbladder, cystic duct,
common bile duct, left and right first order intrahepatic ducts, second order intrahepatic
ducts, and third order intrahepatic ducts for each time interval (0, 5, 10, 15, 30, 45, and 60 
minutes).  Visibility was scored on a scale of 1 to 4 (1=structure not seen, 2=structure
faintly seen, 3=structure seen but not in its entirety, and 4=entire structure seen).  The
maximum diameters of the proximal and distal portions of the common bile duct, the
cystic duct, and the viewable intrahepatic ducts were measured for each time interval on 
transverse images.  The time to maximum visibility score and time to maximum bile duct 
diameter were recorded as well as the maximum visibility score and maximum diameter
for each structure.
Statistical analysis
Descriptive statistics (mean, standard deviation, minimum, and maximum) were
calculated using PROC TABULATE in SAS for Windows 9.3h. Histograms were used to 
visually assess if the measured outcomes were normally distributed using PROC 
UNIVARIATE in SAS for Windows 9.3.  The distributions of the outcome measures 
were not normally distributed.  Accordingly, a non-parametric method, Wilcoxon Rank 



















   
effect of contrast media and the effect of dose on each of the outcomes.  Differences in 
the time to maximum visibility score, time to maximum bile duct diameter, maximum 
visibility score, and maximum bile duct diameter measured were assessed between the 
two contrast media and between the two doses in eight separate models for each of the
structures.  Differences in time to maximum visibility of contrast media in the duodenum 
were also assessed for the different contrast media and doses.  An alpha level of 0.05 was 
used to determine statistical significance for all methods.
Results
The time to maximum visibility score with regards to choice of contrast media 
was not significantly different in the dorsal and ventral aspects of the gallbladder 
(p>0.829) (Table 3.1), but it was significantly different for the cystic duct (p=0.029), 
proximal bile duct (p=0.029), distal bile duct (p=0.029), first order intrahepatic ducts 
(p=0.029), second order intrahepatic ducts (p=0.029), and third order intrahepatic ducts 
(p=0.057) in that the time to the maximum visibility score was longer for Cholografin® 
than for Biliscopin® (Table 3.1).  The time to maximum duct diameter in regards to 
contrast media choice was significantly different for the cystic duct (p=0.057) with the 
maximum diameter being reached faster with Biliscopin® than Cholografin® (Table 3.2).
The choice of contrast media was not significantly different with regards to the time to 
maximum duct diameter for the bile duct and intrahepatic ducts (p>0.086) (Table 3.2).  
The dose of contrast had no significant effects on the time to maximum visibility score
for any of the biliary structures (p>0.142) (Table 3.3).  Differences in the time to 
maximum bile duct diameter due to dose were also not significant in any of the bile ducts 

















maximum visibility score (p>0.429) or the maximum diameter of each bile duct 
(p>0.143) (Tables 3.5 and 3.6).  The dose also had no significant effect on the maximum 
visibility score (p>0.714) or the maximum diameter (p>0.143) (Tables 3.7 and 3.8). 
There was a significant difference between the two contrast agents and the time to 
contrast seen in the duodenum (p=0.057) (Table 3.1).  There was not a significant 
difference with regards to dose in the time it took for contrast to reach the lumen of the
duodenum (p=1.000) (Table 3.3).  Contrast was seen the lumen of the duodenum in five
out of the eight dogs.  Contrast was seen in the duodenum in all four of the dogs 
administered Biliscopin® with time to contrast seen in the lumen ranging from 15 to 45 
minutes.  Contrast was seen in the duodenal lumen in one dog administered Cholografin® 
at 45 minutes.  No adverse reactions to the contrast media were noted.  No variation from 








   
 
   
 
          
 
            
            
           
           
           
            
            
            
           
  
   
     
 
  
Table 3.1 Time to Maximum Visibility Score by Contrast Media
Contrast Media
Biliscopin® Cholografin® 
Time to Maximum Visibility
Score
Time to Maximum Visibility
Score
N Mean StdDev Min Max N Mean StdDev Min Max
Structure
4 37.50 8.66 30.00 45.00 4 36.50 19.47 20.00 60.00VENT GB
DORS GB 4 52.50 8.66 45.00 60.00 4 46.25 9.46 40.00 60.00
CD 4 8.75 2.50 5.00 10.00 4 32.50 14.46 19.00 45.00
PROX BD 4 6.25 2.50 5.00 10.00 4 35.25 11.84 21.00 45.00
DIS BD 4 11.25 2.50 10.00 15.00 4 40.50 15.29 26.00 60.00
1st OD 4 8.75 4.79 5.00 15.00 4 40.00 7.07 30.00 45.00
2nd OD 4 20.00 12.25 5.00 30.00 4 46.75 11.64 32.00 60.00
3rd OD 4 12.50 11.90 5.00 30.00 4 41.75 22.19 15.00 60.00
TCINDUO 4 21.25 16.01 10.00 45.00 4 56.25 7.50 45.00 60.00
VENT GB= ventral gallbladder, DORS GB= dorsal gallbladder, CD= cystic duct, PROX
BD= proximal bile duct, DIS BD= distal bile duct, 1st OD= 1st order intrahepatic ducts, 
2nd OD= 2nd order intrahepatic ducts, 3rd OD= 3rd order intrahepatic ducts, TCINDUO=
time to contrast seen in the lumen of the duodenum, N=number of observation StdDev=












          
 
           
           
            
            
            
            






Table 3.2 Time to Maximum Duct Diameter by Contrast Media
Contrast Media
Biliscopin® Cholografin® 
Time to Maximum Duct 
Diameter
Time to Maximum Duct 
Diameter
N Mean StdDev Min Max N Mean StdDev Min Max
Structure
4 15.00 10.00 10.00 30.00 4 52.50 15.00 30.00 60.00CD
PROX BD 4 21.25 25.94 5.00 60.00 4 52.50 8.66 45.00 60.00
DIS BD 4 52.50 8.66 45.00 60.00 4 56.25 7.50 45.00 60.00
1st ODR 4 28.75 18.87 10.00 45.00 4 48.75 14.36 30.00 60.00
1st ODL 4 28.75 22.50 10.00 60.00 4 49.25 13.50 32.00 60.00
2nd OD 4 22.50 18.48 5.00 45.00 4 52.50 8.66 45.00 60.00
3rd OD 4 30.00 12.25 15.00 45.00 3 40.67 16.77 30.00 60.00
CD= cystic duct, PROX BD= proximal bile duct, DIS BD= distal bile duct, 1st ODR= 
right 1st order intrahepatic duct, 1st ODL= left 1st order intrahepatic duct, 2nd OD= 2nd 
order intrahepatic ducts, 3rd OD= 3rd order intrahepatic ducts, N= number of 
observation, StdDev= standard deviation, Min= minimum, Max= maximum Time=








   
 
   
 
          
 
            
            
           
           
           
            
            
            






Table 3.3 Time to Maximum Visibility Score by Dose
Dose
0.5mL/kg 1mL/kg
Time to Maximum Visibility
Score
Time to Maximum Visibility
Score
N Mean StdDev Min Max N Mean StdDev Min Max
Structure
4 39.00 17.15 21.00 60.00 4 35.00 12.25 20.00 45.00VENT GB
DORS GB 4 55.00 10.00 40.00 60.00 4 43.75 2.50 40.00 45.00
CD 4 21.50 16.50 10.00 45.00 4 19.75 17.80 5.00 45.00
PROX BD 4 20.25 17.80 5.00 45.00 4 21.25 19.74 5.00 45.00
DIS BD 4 27.75 22.51 10.00 60.00 4 24.00 17.15 10.00 45.00
1st OD 4 27.50 17.56 10.00 45.00 4 21.25 19.74 5.00 45.00
2nd OD 4 35.00 15.81 15.00 50.00 4 31.75 22.49 5.00 60.00
3rd OD 4 28.75 22.50 10.00 60.00 4 25.50 26.29 5.00 60.00
TCINDUO 4 41.25 18.87 15.00 60.00 4 36.25 27.50 10.00 60.00
VENT GB= ventral gallbladder, DORS GB= dorsal gallbladder, CD= cystic duct, PROX
BD= proximal bile duct, DIS BD= distal bile duct, 1st OD= 1st order intrahepatic ducts, 
2nd OD= 2nd order intrahepatic ducts, 3rd OD= 3rd order intrahepatic ducts, 
TCINDUO= time to contrast seen in the lumen of the duodenum, N= number of













          
 
           
           
            
            
            
            
            




Table 3.4 Time to Maximum Duct Diameter by Dose
Dose
0.5mL/kg 1mL/kg
Time to Maximum Duct 
Diameter
Time to Maximum Duct 
Diameter
N Mean StdDev Min Max N Mean StdDev Min Max
Structure
4 27.50 23.63 10.00 60.00 4 40.00 24.49 10.00 60.00CD
PROX BD 4 46.25 27.50 5.00 60.00 4 27.50 20.21 10.00 45.00
DIS BD 4 52.50 8.66 45.00 60.00 4 56.25 7.50 45.00 60.00
1st ODR 4 25.00 15.81 10.00 45.00 4 52.50 8.66 45.00 60.00
1st ODL 4 40.50 24.24 10.00 60.00 4 37.50 19.36 15.00 60.00
2nd OD 4 45.00 12.25 30.00 60.00 4 30.00 26.77 5.00 60.00
3rd OD 4 30.50 1.00 30.00 32.00 3 40.00 22.91 15.00 60.00
CD= cystic duct, PROX BD= proximal bile duct, DIS BD= distal bile duct, 1st ODR=
right 1st order intrahepatic duct, 1st ODL= left 1st order intrahepatic duct, 2nd OD= 2nd 
order intrahepatic ducts, 3rd OD= 3rd order intrahepatic ducts, N= number of 
observation, StdDev= standard deviation, Min= minimum, Max= maximum Time=








      
          
 
            
            
           
           
           
            
            




   
  
Table 3.5 Maximum Visibility Score by Contrast Media
Contrast Media
Biliscopin® Cholografin® 
Maximum Visibility Score Maximum Visibility Score
N Mean StdDev Min Max N Mean StdDev Min Max
Structure
4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00VENT GB
DORS GB 4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00
CD 4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00
PROX BD 4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00
DIS BD 4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00
1st OD 4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00
2nd OD 4 4.00 0.00 4.00 4.00 4 3.50 0.58 3.00 4.00
3rd OD 4 2.50 0.58 2.00 3.00 4 2.50 1.00 2.00 4.00
VENT GB= ventral gallbladder, DORS GB= dorsal gallbladder, CD= cystic duct, PROX
BD= proximal bile duct, DIS BD= distal bile duct, 1st OD= 1st order intrahepatic ducts, 
2nd OD= 2nd order intrahepatic ducts, 3rd OD= 3rd order intrahepatic ducts, N= number








    
          
 
           
           
           
            
            
            
            
    
 
  
Table 3.6 Maximum Bile Duct Diameter by Contrast Media
Contrast Media
Biliscopin® Cholografin® 
Maximum Duct Diameter Maximum Duct Diameter
N Mean StdDev Min Max N Mean StdDev Min Max
Structure
4 3.93 0.87 3.00 5.10 4 4.13 0.67 3.50 4.80CD
PROX BD 4 3.30 0.84 2.60 4.50 4 3.80 1.54 2.40 5.70
DIS BD 4 3.35 0.44 3.10 4.00 4 4.38 1.34 2.60 5.60
1st ODR 4 2.03 0.56 1.50 2.80 4 2.70 0.57 2.00 3.30
1st ODL 4 2.03 0.26 1.80 2.30 4 2.05 0.35 1.70 2.40
2nd OD 4 2.03 0.36 1.70 2.50 4 1.99 0.55 1.40 2.70
3rd OD 4 1.45 0.19 1.20 1.60 3 1.81 0.48 1.40 2.34
CD= cystic duct, PROX BD= proximal bile duct, DIS BD= distal bile duct, 1st ODR=
right 1st order intrahepatic duct, 1st ODL= left 1st order intrahepatic duct, 2nd OD= 2nd 
order intrahepatic ducts, 3rd OD= 3rd order intrahepatic ducts, N= number of 
observation, StdDev= standard deviation, Min=minimum, Max= maximum, Duct 








      
          
 
            
            
           
           
            
            
            






Table 3.7 Maximum Visibility Score by Dose
Dose
0.5mL/kg 1mL/kg
Maximum Visibility Score Maximum Visibility Score
N Mean StdDev Min Max N Mean StdDev Min Max
Structure
4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00VENT GB
DORS GB 4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00
CD 4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00
PROX BD 4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00
DIS BD 4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00
1st OD 4 4.00 0.00 4.00 4.00 4 4.00 0.00 4.00 4.00
2nd OD 4 3.75 0.50 3.00 4.00 4 3.75 0.50 3.00 4.00
3rd OD 4 2.75 0.96 2.00 4.00 4 2.25 0.50 2.00 3.00
VENT GB= ventral gallbladder, DORS GB= dorsal gallbladder, CD= cystic duct, PROX
BD= proximal bile duct, DIS BD= distal bile duct, 1st OD= 1st order intrahepatic ducts, 
2nd OD= 2nd order intrahepatic ducts, 3rd OD= 3rd order intrahepatic ducts, N= number








    
          
 
           
           
           
            
            
            
            
   
 
  
Table 3.8 Maximum Duct Diameter Measured by Dose
Dose
0.5mL/kg 1mL/kg
Maximum Duct Diameter Maximum Duct Diameter
N Mean StdDev Min Max N Mean StdDev Min Max
Structure
4 3.98 0.57 3.50 4.80 4 4.08 0.95 3.00 5.10CD
PROX BD 4 3.15 0.90 2.40 4.40 4 3.95 1.42 2.70 5.70
DIS BD 4 3.60 1.35 2.60 5.60 4 4.13 0.82 3.20 5.20
1st ODR 4 2.45 0.84 1.50 3.30 4 2.28 0.46 1.80 2.80
1st ODL 4 2.03 0.26 1.80 2.30 4 2.05 0.35 1.70 2.40
2nd OD 4 2.27 0.41 1.80 2.70 4 1.75 0.29 1.40 2.10
3rd OD 4 1.76 0.41 1.40 2.34 3 1.40 0.20 1.20 1.60
CD= cystic duct, PROX BD= proximal bile duct, DIS BD= distal bile duct, 1st ODR=
right 1st order intrahepatic duct, 1st ODL= left 1st order intrahepatic duct, 2nd OD= 2nd 
order intrahepatic ducts, 3rd OD= 3rd order intrahepatic ducts, N= number of 
observation, StdDev= standard deviation, Min=minimum, Max= maximum, Duct 





















All transverse images have the same directional orientation
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Sagittal Reconstruction Biliscopin (1 mL/kg)






























































                                            
 
                              
  
 
  Cranial Caudal
Biliscopin® (1mL/kg)
Cholografin® (1mL/kg)





















    
 
Discussion
Advantages of MSCTC include that it is non-invasive, it can be performed with 
injectable sedation in dogs, it can provide functional information about the biliary system, 
and it can provide detailed cross-sectional and three-dimensional images of biliary
anatomy.  This procedure has been shown to be diagnostically relevant and helpful in 
multiple human studies involving hepatobiliary disease as well as pre- and post-operative
hepatobiliary surgical cases.48, 52, 54-57, 59-61, 69 Pre-operatively, it has been used in humans 
for detection of stones or other causes of biliary obstruction and in visualizing the biliary
anatomy to evaluate for any anatomic variations that could increase the risk of ductal 
injuries.60, 61 Post-operatively, it has been used to evaluate for leakage and stricture at the
surgical site.  Our study established that MSCTC is feasible in the normal dog and 
produces high quality images of the biliary anatomy.
Multiple contrast dosing ranges and techniques have been studied and used in 
humans for MSCTC.  The majority of human studies report good results using an 
infusion of biliary contrast over a range of 5 to 60 minutes prior to CT imaging, reporting
scan delay times from 5 minutes to 75 minutes.8, 9, 11, 47, 79, 80 In a MSCTC study
performed on normal pigs, an infusion of Biliscopin® was administered over 20 minutes 
and the pigs were then scanned every two minutes for 34 minutes.6 The authors reported 
the optimum imaging time for visualization of the biliary system was 10 to 34 minutes.6 
A cholangiography study combined with CT performed in normal dogs under general 
anesthesia compared three different doses (1 mL/kg, 1.5 mL/kg, and 2 mL/kg) of 
Biliscopin® administered as infusions over 10 minutes.81 Computed tomographic






   
   
 
  








     
   
 
minutes.81 They reported that the 1 mL/kg dose was insufficient for visualizing the 
biliary system and that the 2 mL/kg dose was the most optimal for visualizing the bile 
ducts.81 They also reported that the most optimal time to image the biliary system is 20 
to 40 minutes following a 10 minute infusion of the 2 mL/kg dose of Biliscopin®.81 In 
our study, we based our dosing choices on doses used in previous conventional 
cholangiography studies that were shown to produce good opacification of the biliary
tract in dogs.45, 71, 82 We chose to administer a bolus injection over a constant rate 
infusion because Cholografin® is labeled as a single dose injection agent, and we felt that 
it would be more practical in an animal that was sedated and would save time in a clinical 
setting.45, 82 The infusion method has been reported to decrease the severity side effects 
in humans; however, little has been reported on the adverse effects of biliary specific
contrast in dogs.  No adverse effects from the contrast were seen in any of the dogs used 
in our study.  The infusion method could be studied in normal dogs or dogs with 
hepatobiliary disease in the future using MSCTC.  
Our data showed that the contrast dose made no difference in the time to 
maximum visibility, time to maximum duct diameter, maximum visibility score, or 
maximum duct diameter.  There was a statistical difference in the type of contrast media 
used, however, with Biliscopin® providing a faster time to maximum visibility score in 
almost all structures and a faster time to maximum duct diameter in the cystic duct.  This 
correlates with previous studies in dogs and cats in which Biliscopin® had a faster
excretion rate than other contrast agents and a strong dilating effect on the bile ducts.65, 77 
The type of contrast media had no effect on the maximum visibility score or maximum 






    
   












   
 
 
   
duodenum as contrast was seen in the duodenum in all four dogs that were administered
Biliscopin® and only one dog that was administered Cholografin®.
Subjectively, Biliscopin® provided superior images of the biliary structures based 
on the homogeneity of the ducts and a faster rate of bile duct opacification than 
Cholografin®. The higher dose of 1mL/kg subjectively provided better quality images of 
the bile ducts than the lower dose of 0.5mL/kg in all dogs.  It was determined that the 
most optimal time to scan a patient following injection of Cholografin® was 60 minutes.  
At 60 minutes, the gallbladder, cystic and bile ducts, and first, second, and most of the
third order intrahepatic ducts were opacified and seen clearly.  The optimal time to image
the bile ducts following Biliscopin® administration occurred between 15 to 30 minutes in 
all four dogs.  The opacification of the entire gallbladder, however, was best seen at 60 
minutes in patients administered Biliscopin®.
High quality two-dimensional and three-dimensional reconstructions were
performed in each dog and included multiplanar reconstructions, maximum intensity
projections, and shaded surface display.  All of the reconstructions were helpful in 
evaluating the normal biliary anatomy.  Subjectively, the shaded surface display images
provided the best quality images of all of the biliary structures.  They provided the best 
global viewing of the entire biliary tree and individual structures.
In our original study design, we planned to use only one type of contrast and two 
different doses.  Initially, we chose Cholografin® as our biliary specific contrast agent, 
given that it was the only one available in the United States.  We originally planned to 
scan all eight dogs using this contrast agent.  However, halfway through our data 














   




contrast to complete the project.  As we were unsure when Cholografin® would be
available, we decided to complete the project using an alternative contrast agent still
commercially available outside of the United States.  We chose Biliscopin® (meglumine 
iotroxate) as our replacement contrast to complete the study.
Due to the change of contrast midway through the project, we were also had to 
reconfigure the dose groups.  Of the four dogs in each contrast group, two received the 
lower dose of contrast (0.5mL/kg) and two received the higher dose of contrast (1mL/kg).  
This unfortunately decreased our sample size of eight dogs to four dogs in each contrast 
group.  We recognize our small sample size is a limitation of the study.  There may have
been more differences detected between the two dose groups if the sample population had 
been higher.  While, there was no statistically significant difference between the two dose
groups with regards to the time to maximum visibility and duct diameter as well as the 
maximum visibility scores and maximum bile duct diameters, the higher dose provided 
subjectively better quality images.  The lack of statistically significant difference may
have been due to our visibility scoring system not having enough discernment. If our
scoring system had consisted of a wider range of numbers, such as 3.1 or 4.5 versus just 3 
and 4, we may have detected more statistically significant differences between the two 
dose groups.  More work is needed to determine if the dose of contrast affects the
visibility of biliary structures and the duct diameters.  Difficulty in measuring structures 
of such a small magnitude with our available work station may have also skewed some of 
the statistics with regards to duct diameter.  Regardless of the limitations of our study, we
















   
 
   
Hyperbilirubinemia has been described as a limitation for performing
cholangiography with radiography and MSCT.  In humans and dogs with poor 
hepatobiliary function, elevated plasma bilirubin is associated with unreliable excretion 
of biliary contrast causing non-diagnostic or poor quality CT cholangiography studies.12, 
48, 54, 66-71, 83 In humans, a serum bilirubin of greater than 2.0mg/deciliters (dL) is a good 
predictor of poor contrast excretion.12, 68, 69 However, even in hyperbilirubinemic patients 
it has been shown that, although the biliary tract is not optimally enhanced, it is still 
possible to obtain a diagnostic CTC study to detect abnormalities such as dilation or
obstruction of the bile ducts.48, 68 Other studies in humans have shown that slowly
infusing a biliary specific contrast agent over several hours as opposed to a single 
intravenous injection may allow for increased density of the bile ducts in patients with 
high bilirubin levels (greater than 1.1mg/dL).48, 69 Good contrast enhancement of the 
biliary tree can also be obtained by increasing the dose of contrast material in human 
patients with bilirubin levels greater than 1.5 times normal and then waiting 2-2.5 hours 
after contrast administration to perform the CT scan.54 Several studies evaluating the 
effect of bilirubin on biliary iodipamide (Cholografin®) excretion in dogs suggest that the 
contrast dose can be increased in hyperbilirubinemic patients to obtain adequate 
opacification of the biliary structures and that a prolonged infusion or decrease in contrast 
dose is not indicated.66, 67, 71 Although there has been mixed success with multi-slice
CTC in human patients with bilirubin levels greater than 2 mg/dL, several studies have
shown that diagnostic studies can still be performed in some patients with bilirubin levels 






   
   





    
 
performed using MSCTC in dogs with elevated bilirubin, and this could be a potential 
focus for future studies.  
Endnotes
a Biosound MyLab 50, Esaote North America, Inc., Indianapolis, IN
b Butorphanol, Hospira, Inc., Lake Forrest, IL
c Dexmedetomidine, Hospira Inc., Lake Forrest, IL
d GE Lightspeed, GE Medical Systems, Waukesha, WI
e Cholografin®, Bracco Diagnostics, Princeton, New Jersey
f Biliscopin®, Bayer Group, Berlin, Germany
g Picture Archiving System (PACS), McKesson, Richmond, BC, Canada



















   
CHAPTER IV
CONCLUSION
Our study demonstrated the feasibility of MSCTC in normal dogs.  The key
advantages that make MSCTC ideal for imaging the hepatobiliary system in dogs are that 
it is non-invasive, it provides high quality two and three dimensional images of the
biliary anatomy, it provides functional information regarding biliary kinetics, and it can 
be performed under sedation.  The biliary specific contrast agents we used provided 
excellent opacification of the gallbladder and bile ducts.  Biliscopin® proved to be
superior to Cholografin® by providing subjectively better quality images of the biliary
anatomy in a shorter amount of time.  However, both contrast agents produced high 
quality images of the hepatobiliary system and could be used with MSCT to obtain a 
diagnostic quality study. At this time, Cholografin® is still unavailable but is scheduled
to be released at some point this year.
In our study, no statistically significant differences were seen between the doses
of contrast used.  However, subjectively, the higher dose of 1mL/kg produced better 
quality images of the hepatobiliary system.  Studies have been performed in dogs in the
past using conventional cholangiography investigating different doses of contrast to 
administer to see which provides the best images of the hepatobiliary system.  Some 
studies used infusions of different doses while others used a single bolus injection.  









    
 




   
 
     
  





contrast agents to determine which method of administration provides the best images 
could be performed with MSCTC in normal dogs and in dogs with hepatobiliary disease.
The optimal time to image following contrast injection was shown to be 60 
minutes with Cholografin®. With Biliscopin®, the best time to image the bile ducts 
following contrast injection was 15 to 30 minutes, and the best time to image the
gallbladder was 60 minutes.  Optimal imaging times in dogs using cholangiography with 
radiography were reported to be 30 minutes following injection of Cholografin® for the 
cystic and hepatic ducts and 90 to 120 minutes for the gallbladder.45 A study in pigs 
reported that the optimal imaging time following infusion of Biliscopin® over 20 minutes 
was 10 to 34 minutes.6 Based on our study, the optimal time to image after contrast 
injection is dependent on the type of contrast agent used.
One of the purposes of this study was to serve as a platform for subsequent 
performance of MSCTC in dogs with hepatobiliary disease.  Hepatobiliary disease is 
being diagnosed more commonly in small animals due to advances in imaging.  
Ultrasound is currently considered the gold standard for imaging the hepatobiliary tract in
dogs.26, 33 When compared to MSCTC, however, ultrasound is inferior for demonstrating
the peripheral and intrahepatic bile ducts.1, 2, 5 MSCTC produces detailed, high resolution 
images of all of the biliary anatomy.  Future work in dogs with hepatobiliary disease
using MSCTC could demonstrate if this technique would provide us with any additional 
diagnostic information that could not be obtained with the more commonly used imaging
modalities. 
Clinical situations in which MSCTC could be beneficial in the dog include


















invasion of or metastasis to the bile ducts with a hepatic mass, or a suspected gallbladder 
rupture that cannot be proven on ultrasound.  Other indications for performing MSCTC in 
the dog include cholelithiasis or choledocholithiasis, cholecystitis, gallbladder mucoceles, 
neoplasia of the hepatobiliary structures, or extra-hepatic biliary tract rupture or 
obstruction.1-3 Although this study was limited to hounds and hound mixes, MSCTC 
should be feasible in all breeds given that the anatomy is relatively the same in all dogs.  
MSCTC could also be investigated in dogs with hyperbilirubinemia, as it has been 
labeled a limitation of conventional cholangiography studies in the past.  It would be
clinically important to know how high the bilirubin has to be for MSCTC to be non-
diagnostic.  Evaluation of the rate of excretion of biliary contrast in dogs with 
hepatobiliary disease or with hyperbilirubinemia could also be further studied as well as 
the effect of cholecystokinin on biliary contrast excretion.  Further investigation of
MSCTC in dogs with hepatobiliary disease could aid in the earlier diagnosis and 
treatment of these diseases in the future.
A current limitation to the feasibility of this technique becoming widely available 
is the fact that very few veterinary or referral hospitals have 64-multi-slice CT scanners.  
However, many veterinary hospitals now have some type of multi-slice scanner.  This 
technique could be performed using different types of multi-slice scanners to see what 
type of image quality could be obtained from each one.  The images obtained by
performing this technique could also be used as an aid for teaching cross-sectional and 










Based on our findings, future work in dogs with hepatobiliary disease using
MSCTC will include the following recommendations:  Cholografin® used at 1mL/kg with 
a post-injection scan time of 60 minutes for optimum biliary tract visualization or
Biliscopin® used at 1 mL/kg with a post-injection scan time of 30 minutes for optimal 
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